{"title":"MASLD 的新疗法和最新临床实践指南","authors":"Elizabeth E. Powell","doi":"10.1038/s41575-024-01014-y","DOIUrl":null,"url":null,"abstract":"The year 2024 was momentous for metabolic dysfunction-associated steatotic liver disease (MASLD): the approval of the first medication for treatment of at-risk metabolic dysfunction-associated steatohepatitis, updated guidelines on the screening, diagnosis and treatment of MASLD, and liver stiffness measurement as an important surrogate marker for liver-related outcomes in MASLD.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":null,"pages":null},"PeriodicalIF":45.9000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A new treatment and updated clinical practice guidelines for MASLD\",\"authors\":\"Elizabeth E. Powell\",\"doi\":\"10.1038/s41575-024-01014-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The year 2024 was momentous for metabolic dysfunction-associated steatotic liver disease (MASLD): the approval of the first medication for treatment of at-risk metabolic dysfunction-associated steatohepatitis, updated guidelines on the screening, diagnosis and treatment of MASLD, and liver stiffness measurement as an important surrogate marker for liver-related outcomes in MASLD.\",\"PeriodicalId\":18793,\"journal\":{\"name\":\"Nature Reviews Gastroenterology &Hepatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":45.9000,\"publicationDate\":\"2024-11-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Gastroenterology &Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41575-024-01014-y\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Gastroenterology &Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41575-024-01014-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
A new treatment and updated clinical practice guidelines for MASLD
The year 2024 was momentous for metabolic dysfunction-associated steatotic liver disease (MASLD): the approval of the first medication for treatment of at-risk metabolic dysfunction-associated steatohepatitis, updated guidelines on the screening, diagnosis and treatment of MASLD, and liver stiffness measurement as an important surrogate marker for liver-related outcomes in MASLD.
期刊介绍:
Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication.
The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information.
Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.